Abiopharma

New Form SCHEDULE 13D/A - ESSA Pharma Inc. Filed: 2025-08-07 AccNo: 0000921895-25-002132 Size: 33 KB

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

New Form PRE 14A - Predictive Oncology Inc. Filed: 2025-08-07 AccNo: 0001171843-25-005187 Size: 137 KB

New Form 4 - Liquidia Corp Filed: 2025-08-07 AccNo: 0001104659-25-075216 Size: 5 KB

New Form 8-K - LIFECORE BIOMEDICAL, INC. \DE\ Filed: 2025-08-07 AccNo: 0001005286-25-000106 Size: 372 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 4 - Claritev Corp Filed: 2025-08-07 AccNo: 0001793229-25-000137 Size: 4 KB

Secure Boot On Computers: Complete Guide

New Form 10-Q - LifeStance Health Group, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-105096 Size: 8 MB

New Form 4 - NEUROCRINE BIOSCIENCES INC Filed: 2025-08-07 AccNo: 0000914475-25-000164 Size: 4 KB

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sensus Healthcare Reports Second Quarter 2025 Financial Results

New Form 4 - STRYKER CORP Filed: 2025-08-07 AccNo: 0000310764-25-000112 Size: 4 KB

New Form S-8 - CytomX Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001193125-25-175473 Size: 198 KB